AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01974193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Floseal
Description: application of floseal on intervention arm
Study NCT03873038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2060
Description: Part 1: Single doses (8 mg, 20 mg, or 40 mg) of MK-2060 will be administered via IV infusion on Day 1.~Part 2: Three doses of 25 mg of MK- 2060 administered via IV infusion on Days 1, 3 and 5; Followed by single doses of 25 mg of MK-2060 administered via IV infusion on Days 8, 15, and 22.
Study NCT03873038 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Part 1: Single dose of placebo will be administered via IV infusion on Day 1. Part 2: Three doses of placebo administered via IV infusion on Days 1, 3 and 5; Followed by single doses of placebo administered via IV infusion on Days 8, 15, and 22.
Study NCT02135523 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: involved-field radiation therapy
Description: Participants will receive involved-field radiotherapy (external beam radiotherapy or brachytherapy) over 45Gy for residual or locoregionally recurrent epithelial ovarian cancer after definitive treatment. Patients will be treated with 1.8-2.0Gy fraction, five times per week. It starts 2 weeks later of chemotherapy.
Study NCT03398564 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Erector Spinae Plan Block
Description: The trocar site incision was done 15 minutes after the block in the three groups. The skin was disinfected with chlorhexidine solution, and the high-frequency transducer was isolated with a sterile disposable plastic cover and gel. The patient was placed in lateral position. A high-frequency linear ultrasound probe was placed longitudinally lateral to the T8 spinous process by 3 cm. After identification of the 3 muscles superficial to the hyperechoic transverse process shadow as follows: trapezius, rhomboid major, and erector spinae. The needle was introduced in a cephalo-caudal orientation. The needle tip was positioned fascial plane between rhomboid major and erector spinae muscles. Hydrodissection by 1-2 ml of normal saline to visualize the plan, then deposition of local anesthetic was done. A total of 20 mL of 0.25% bupivacaine was injected here. The same procedure was repeated on the other side.
Study NCT03398564 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spinae Plan Block
Description: The trocar site incision was done 15 minutes after the block in the three groups. The skin was disinfected with chlorhexidine solution, and the high-frequency transducer was isolated with a sterile disposable plastic cover and gel. The patient was placed in lateral position. A high-frequency linear ultrasound probe was placed longitudinally lateral to the T8 spinous process by 3 cm. After identification of the 3 muscles superficial to the hyperechoic transverse process shadow as follows: trapezius, rhomboid major, and erector spinae. The needle was introduced in a cephalo-caudal orientation. The needle tip was positioned fascial plane between rhomboid major and erector spinae muscles. Hydrodissection by 1-2 ml of normal saline to visualize the plan, then deposition of local anesthetic was done. A total of 20 mL of 0.25% bupivacaine was injected here. The same procedure was repeated on the other side.
Study NCT03398564 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Oblique subcostal TAP
Description: ultrasound-guided bilateral oblique subcostal TAP block with bupivacaine 0.25% (20ml on each side)
Study NCT03883321 — intervention group
Intervention type: OTHER
Intervention: Cognitive behavioral stress management
Description: Management of patients in 10 group sessions with cognitive and behavioral therapies associated with relaxation in order to learn how to manage stress
Study NCT01389050 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiotherapy
Description: Radiotherapy for the treatment of retroperitoneal sarcoma. IMRT will be 50.4 Gy given in 28 fractions.
Study NCT01389050 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Daily Cone Beam CT
Description: Images and information from the daily CT will be used for the repositioning of the patient prior to their treatments as per standard procedures.
Study NCT01348048 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Specialised palliative care (SPC)
Description: The interventions given by the SPC centres follow the the WHO and the EAPC guidelines for palliative care. It is not possible in advance to describe the interventions more specifically as these will be adjusted to each particular patient. As part of the study the medical records of all patients in the intervention group will be reviewed with the purpose of describing the interventions given for the different symptoms and problems.
Study NCT03687320 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: B-Cure Pro
Description: The B-Cure laser Pro is a portal, non-invasive, low level laser therapy device, that emits light in the near infrared (808nm) over an area of 1X4.5 cm2 with power output of 250mW, and energy dose of 5J/min.
Study NCT00786799 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Omega-3 Fatty Acids
Description: Omega-3 Fatty Acids in orange pudding form~1 packet two times per day
Study NCT03629015 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stemchymal®
Description: ALF/ ACLF patients will receive Stemchymal® through intravenous infusion
Study NCT02772744 — intervention group
Intervention type: DRUG
Intervention: Daclatasvir 60 MG Oral Tablet [Daklinza]
Description: Daclatasvir (60 MG) is a potent, pan-genotypic inhibitor of the HCV NS5A protein
Study NCT02772744 — intervention group
Intervention type: DRUG
Intervention: Sofosbuvir 400 MG Oral Tablet [Sovaldi]
Description: Sofosbuvir (400 MG) is a nucleotide analogue HCV NS5B polymerase inhibitor
Study NCT02772744 — intervention group
Intervention type: DRUG
Intervention: Ribavirin Oral Product
Description: Ribavirin (twice-daily) dosed according to body weight (\<75 kg, 1000 mg daily; ≥75 kg, 1200 mg daily)
Study NCT01748097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium bicarbonate 4.2%
Study NCT04873544 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ERAS protocols for TKA
Description: ERAS protocols for TKA
Study NCT02240836 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention. Exercise
Description: Physical activity. Attendance in exercise groups 60 min. twice a week and exercise at home 120 min per week. Intervention for 12 months.
Study NCT02987465 — intervention group
Intervention type: DRUG
Intervention: Darbepoetin Alfa
Description: Darbepoetin is not a study drug and is prescribed as part of routine treatment of anaemia in CKD1. Darbepoetin is licensed for use for the treatment of anaemia in the context of CKD. It will be provided as part of the standard clinical care of the renal patients in this study. Healthy Volunteers will not be treated with Darbepoetin.
Study NCT02987465 — intervention group
Intervention type: DRUG
Intervention: Acetylcholine
Description: Acetylcholine is being used as a challenge agent in this study and assesses NO-mediated vasodilation
Study NCT02987465 — intervention group
Intervention type: DRUG
Intervention: Noradrenaline
Description: Noradrenaline is being used as a challenge agent in this study and is an endogenous a1 adrenoceptor agonist
Study NCT02987465 — intervention group
Intervention type: DRUG
Intervention: BQ 123
Description: BQ 123 is being used as a challenge agent in this study and is an (Endothelin A) ETA receptor agonist.
Study NCT02416596 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hysteroscopy
Description: Office hysteroscopy will be performed during the Luteal phase of the proceeding menstrual cycle.~All OH (office hysteroscopy) procedures will be performed with a vaginoscopic approach without utilizing a speculum and applying traction to the cervix with a tenaculum.~Antibiotic prophylaxis: None OH will be cancelled until after treatment of vaginal infection.
Study NCT02416596 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hysteroscope
Description: The device used is a rigid hysteroscope (continuous flow, 30 degree forward oblique view) assembled in a 4-mm diameter diagnostic sheath with an atraumatic tip (Karl Storz Endoscopy).~Illumination: High intensity cold light source and fiberoptic cable Distention medium: solution of 0.9% normal saline with pressure at 100-120 mmHg
Study NCT02729441 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ramipril
Description: Comparison of two renin angiotensin aldosterone inhibitors
Study NCT02729441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: perindopril
Description: Comparison of two renin angiotensin aldosterone inhibitors
Study NCT00592124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate
Description: 300 mg tablet daily
Study NCT00592124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir gel
Description: 1 gm/100 ml of 1% gel vaginally daily
Study NCT00703924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WR 279,396
Description: A topical cream containing 15% paromomycin and 0.5% gentamicin. Approximately 0.0005 mL per mm2 of skin lesion
Study NCT00703924 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Topical cream vehicle. Approximately 0.0005 mL per mm2 of skin lesion
Study NCT00323648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Whether or not giving postoperatively antibiotics to patients with an uncomplicated acute cholecystitis
Description: Whether or not giving postoperatively antibiotics to patients with an uncomplicated acute cholecystitis.
Study NCT00478842 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation
Description: Deep brain stimulation
Study NCT01916382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitisinone
Description: drug
Study NCT00842556 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: Tablets, Oral, 20 mg, Single Dose
Study NCT00842556 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: Tablets, Oral, 4 mg, Single Dose
Study NCT00842556 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: Tablets, Oral, 100 mg, Single Dose
Study NCT03853135 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: measurement of serum endocan
Description: measurement of serum levels of endocan
Study NCT04041271 — intervention group
Intervention type: OTHER
Intervention: Cervical range of motion (CROM)
Description: Subjects will perform full-range cervical flexion, extension, side-bending and rotation actively in sitting position. In supine position, cervical flexion-rotation will be performed passively by the assessor.
Study NCT04041271 — intervention group
Intervention type: OTHER
Intervention: Pressure pain threshold (PPT)
Description: A digital algometer with rubber head will be used to apply pressure on the muscles of subjects. When the subjects start to feel pain, the algometer will be removed immediately.
Study NCT04041271 — intervention group
Intervention type: OTHER
Intervention: Cranial-cervical angle (CCA)
Description: Subjects will stand in a relaxed position with colour markers on the earlobe and C7 spinous process. A photo of the head posture will be taken to calculate the included angle between the markers and the horizontal line.
Study NCT04041271 — intervention group
Intervention type: OTHER
Intervention: Jaw kinematics
Description: Jaw kinematics is measured by Ultrasonic Jaw Motion Analyzer (Zebris). The subjects will perform jaw opening, closing, lateral left, lateral right and protrusion for three times.
Study NCT04021264 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Ropivacaine-Sufentanil
Description: Local anesthetic injection
Study NCT04021264 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine-Sufentanil
Description: Local anesthetic injection
Study NCT04021264 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Dextrose 5
Description: Sham injection
Study NCT04041271 — intervention group
Intervention type: OTHER
Intervention: Muscle activation
Description: Surface electromyography is used to assess the activities of bilateral masseter, anterior temporalis, sternocleidomastoid muscle and upper trapezius. Subjects will perform jaw resting and clenching.
Study NCT02196935 — intervention group
Intervention type: OTHER
Intervention: clinical course
Description: Detailed presentation including labs, demographics, imaging of those who undergo ERCP/EUS with be prospectively recorded. Details of procedure including sedation strategy and success will be collected. Results of procedure including final pathology results with be recorded.
Study NCT03479502 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone Injectable Product
Description: 3 intra-articular injections of Methylprednisolone Injectable Product spaced every two weeks
Study NCT03211494 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: INTELLiVENT-ASV
Description: INTELLiVENT-ASV, with software 2.60
Study NCT03211494 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional lung protective ventilation
Description: Lung protective ventilation according to the ARDSnet guidelines
Study NCT02219854 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic gastrectomy
Study NCT02219854 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open gastrectomy
Study NCT03214575 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional method
Study NCT03214575 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: GPS Method
Study NCT02999906 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Treprostinil
Description: Sustained release oral tablets for three times daily administration
Study NCT02999906 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (sugar pill) for three times daily oral administration
Study NCT03730532 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy Guided Self Help
Description: 6-week manualised Cognitive Behavioural Therapy Guided Self Help
Study NCT03730532 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Analytic Therapy Guided Self Help
Description: 6-week manualised Cognitive Analytic Therapy Guided Self Help
Study NCT02917785 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Karman curettage
Study NCT04021264 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dextrose 5
Description: Sham injection
Study NCT01541826 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Chokeberry Extract
Description: Consumption of 2 x 250 mg chokeberry extract capsules daily for 12 weeks.
Study NCT01541826 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: Color-matched rice powder pill, 2 x 250 mg/day for 12 weeks
Study NCT01541826 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chokeberry extract capsule, acute
Description: Chokeberry extract capsule, 2 x 250 mg, one-time dose.
Study NCT01565291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: florbetapir F 18
Description: IV injection, 370MBq (10mCi), single dose
Study NCT04233281 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kori tofu
Description: 16.5 gram Kori-tofu mixed in a high carbohydrate test meal
Study NCT04233281 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Whey protein
Description: high carbohydrate test meal with whey protein, matched in macronutrient content
Study NCT01289808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucose 25%
Description: 1ml of glucose 25% once
Study NCT01289808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucose 25%
Description: 1ml glucose once per os
Study NCT04029467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: addition of dexmedetomidine to ropivacaine as an adjuvant in ESP block to assess wether or not it prolongs its duration of action
Study NCT04029467 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: addition of dexmedetomidine to ropivacaine as an adjuvant in ESP block to assess wether or not it prolongs its duration of action
Study NCT02673775 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Clean Air
Description: Subjects will have the clean air exposure first, followed by the ozone exposure
Study NCT03479502 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline Injection
Description: 3 intra-articular injections of Doxycycline Injection spaced every two weeks
Study NCT04617197 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation with frequency-specific microcurrent resonant therapy
Description: Transcutaneous electrical nerve stimulation with frequency-specific microcurrent resonant therapy using (Dragon Waves Resonant Home Care Electronic Nerve Stimulator (DW-1330), Taiwan Resonance Wave Research Co., Taiwan R.O.C,)
Study NCT02673775 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ozone
Description: Subjects will have the ozone exposure first, followed by the clean air exposure
Study NCT02815228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY987517
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z43-034)
Study NCT01365273 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mepitel One
Description: Dressing
Study NCT04617197 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation with frequency-specific microcurrent resonant therapy
Description: Transcutaneous electrical nerve stimulation with frequency-specific microcurrent resonant therapy using (Dragon Waves Resonant Home Care Electronic Nerve Stimulator (DW-1330), Taiwan Resonance Wave Research Co., Taiwan R.O.C,)
Study NCT04617197 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation with frequency-specific microcurrent resonant therapy
Description: Transcutaneous electrical nerve stimulation with frequency-specific microcurrent resonant therapy using (Dragon Waves Resonant Home Care Electronic Nerve Stimulator (DW-1330), Taiwan Resonance Wave Research Co., Taiwan R.O.C,)
Study NCT02406859 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bowel Biofeedback
Description: Subjects will complete 2 sessions twice a week for 6 weeks of bowel biofeedback training. Subjects will be asked to squeeze and bear down for a period of 5 seconds followed by rest for 10seconds. Following the training, each subject will complete similar training at home for 6 weeks.
Study NCT02406859 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Anorectal Manometry
Description: Subjects will undergo an anorectal manometry to establish baseline pressure characteristics. If subjects qualify for biofeedback training, they will complete two additional manometries to track the changes occuring during training.
Study NCT03474978 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peripherally Inserted Central Venous Cather (PICC)
Description: Location of the PICC insertion will be randomized and compared
Study NCT04132206 — intervention group
Intervention type: OTHER
Intervention: stool sampling
Description: Participants will provide two stool samples: one collected the day of inclusion and a second, six months later
Study NCT00300261 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth monitoring
Description: Experimental group receives telehealth monitoring equipment in their homes for the duration of home care. Equipment includes blood pressure cuff, scale, and pulse oximeter, or glucometer as needed. Two home care nurses provide video visits with subjects on the days when the home care nurse does not visit. Patients use the equipment daily and the results are downloaded to the nurse's computer at the home care agency where they are checked daily. The nurse acts on any abnormal readings by calling the patient, the home care nurse, or the physician.
Study NCT02905695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chirocaine
Study NCT02420704 — intervention group
Intervention type: PROCEDURE
Intervention: Embryo transfer
Description: For fresh cycles, embryos were transferred 3-5 days after oocyte retrieval; For frozen thawed cycles, embryos were transferred 3-5 days after starting to use progesterone based on the stage of cryopreservation.
Study NCT02905695 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03780920 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: manual therapy/osteopathy
Description: In this group, children will benefit from early osteopathic treatment over a period ranging from the third day to 4 months. The number of sessions will not be fixed, on average, 3 sessions will be carried out during this period at the University Hospital of Montpellier.~The duration of the session will be between 20 minutes to 30 or even 40 minutes
Study NCT02037594 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sexual Health Counseling
Description: This brief intervention presents PrEP within the context of a patient's comprehensive sexual health plan and is designed to enhance decision-making around PrEP use and decrease sexual risk taking.
Study NCT02037594 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Adherence Intervention
Description: This brief intervention is provides standard of care PrEP adherence information plus specific counseling, troubleshooting, and support.